Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning
Yang-Min
YM
PharmD, Bldg 10/Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA.
Gulley
James L
JL
Arlen
Philip M
PM
Woo
Sukyung
S
Steinberg
Seth M
SM
Wright
John J
JJ
Parnes
Howard L
HL
Trepel
Jane B
JB
Lee
Min-Jung
MJ
Kim
Yeong Sang
YS
Sun
Haihao
H
Madan
Ravi A
RA
Latham
Lea
L
Jones
Elizabeth
E
Chen
Clara C
CC
Figg
William D
WD
Dahut
William L
WL
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary / Q000601:surgery; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068258:Bevacizumab; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D000077143:Docetaxel; D015536:Down-Regulation; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D009919:Orchiectomy; D011241:Prednisone / Q000008:administration & dosage; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab; D013792:Thalidomide; D017430:Prostate-Specific Antigen; D011241:Prednisone